Zobrazeno 91 - 100
of 6 487
pro vyhledávání: '"59"'
Autor:
Yi Sun, Wenna Jiang, Lu Sun, Li Ren, Runfen Cheng, Zhuozhi Wang, Rui Liu, Yongzi Chen, Duo Zuo, Xinwei Zhang, Fan Tang
Publikováno v:
Cancer Biology & Medicine. 19:1029-1046
Objective: The main reasons for the poor prognoses of pancreatic adenocarcinoma (PA) patients are rapid early-stage progression, advanced stage metastasis, and chemotherapy resistance. Identification of novel diagnostic and prognostic biomarkers of P
Autor:
Hiroki Ishihara, Takashi Ikeda, Hiroaki Shimmura, Toshio Takagi, Hideki Ishida, Kazunari Tanabe, Junpei Iizuka, Kazutaka Nakamura, Hidekazu Tachibana, Kazuhiko Yoshida, Hirohito Kobayashi, Hironori Fukuda, Yasunobu Hashimoto, Tsunenori Kondo, Yuki Nemoto
Publikováno v:
Targeted Oncology. 16:493-502
It remains unclear how early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events affects the outcome of previously untreated metastatic renal cell carcinoma (mRCC). To investigate the prognostic impact of the earl
Autor:
Esin Celik, Osama Shiraz Shah, Atilla Soran, Serdar Ugras, Adrian V. Lee, Peter C. Lucas, Mustafa Sahin, Beth A. Knapick
Publikováno v:
Clinical Breast Cancer. 21:210-217
Background Identification of genomic alterations present in cancer patients may aid in cancer diagnosis, prognosis and therapeutic target discovery. In this study, we aimed to identify clinically actionable variants present in stage IV breast cancer
Autor:
Karolina A. Plonowska-Hirschfeld, Patrick K. Ha, Ramez Philips, Aru Panwar, Russell B. Smith, Andrew Coughlin, Jeremy D. Richmon, Edgar Ochoa, Farhoud Faraji, Matthew E. Herberg, Jeffrey J. Houlton, Charles S. Coffey, William R. Ryan, Bridget V. MacDonald, Arnaud F. Bewley, Theodore A Gobillot, Trevor Hackman, Aaron L. Zebolsky, Jonathan Mallen-St. Clair, Mary Jue Xu, Carole Fakhry, Joseph Curry, Arjun S. Joshi, Andrew J Holcomb, David Cognetti
Publikováno v:
Cancer. 127:3092-3106
Background The oncologic outcomes of surgery alone for patients with American Joint Committee on Cancer 7th edition (AJCC 7th) pN2a and pN2b human papillomavirus-associated oropharynx squamous cell carcinoma (HPV+OPSCC) are not clear. Methods The aut
Autor:
Jennifer M. Specht, Vijayakrishna K. Gadi, Hannah M. Linden, Pavani Chalasani, Vicky Wu, Kiah J. Farr, Stephanie Parker, Alex Liu, Isaac C. Jenkins
Publikováno v:
Breast Cancer Research and Treatment
Background Treatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited. In a phase III trial, eribulin demonstrated a significant improvement in overall survival compared to treatment of physician’s cho
Autor:
Jianming Xu, Lihong Wu, Huan Chen, Guanxiong Zhang, Beibei Mao, Chuanhua Zhao, Tianshu Liu, Yiyi Yu, Shoujian Ji, Keyan Yang, Ying Hu, Dandan Liang, Henghui Zhang
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2669-2679
Immune checkpoint blockade (ICB) of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint pathway has led to unprecedented advances in cancer therapy. However, the overall response rate of anti-PD-1/PD-L1 monothera
Autor:
Kevin Tran, Negin Rahimzadeh, Matias A. Bustos, Xiaoqing Zhang, Carol Nishikubo, Grace Chang, Dave S.B. Hoon
Publikováno v:
Cancer Research. 81:PS2-17
Background: Breast cancer (BC) is a heterogeneous disease and difficult to treat once metastasis occurs. Thus, determining blood molecular biomarkers that allow for early diagnosis would help to identify BC patients at higher risk. MicroRNAs (miRs) a
Autor:
Thibaut Sanglier, D. Tesarowski, Patricia Luhn, Eleonora Restuccia, Anita Fung, Carlos Flores, Preet K. Dhillon, Devin Incerti, Vincent Antao
Publikováno v:
Cancer Research. 81:PS10-20
OBJECTIVES Over the last decade, new treatment options have transformed the standard of care for patients (pts) with HER2-positive EBC and the treatment landscape continues to evolve. The primary objectives of our study were (1) to describe and compa
Autor:
Baris Turkbey, Peter A. Pinto, Joanna H. Shih, Maria Merino, Peter L. Choyke, Ravi A. Madan, John R. Bright, Stephanie Harmon, Guinevere Chun, Fatima Karzai, Huihui Ye, Amy Hankin, Scott Wilkinson, Anna Couvillon, Marijo Bilusic, Lisa M. Cordes, Nicolas T. Terrigino, David J. VanderWeele, Rosina T. Lis, William L. Dahut, Nicole V. Carrabba, Stephanie M. Walker, Monique N. Williams, James L. Gulley, Adam G. Sowalsky
Publikováno v:
Clin Cancer Res
Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the pot
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:23-30
The ideal starting dose for an oncology first-in-patient (FIP) trial should be low enough to be safe but not too far removed from therapeutically relevant doses. A low starting dose combined with small dose increments could lead to a lengthy dose esc